Merrill Lynch Keeps a Buy Rating on Illumina (ILMN)


In a report released today, Derik De Bruin from Merrill Lynch reiterated a Buy rating on Illumina (ILMN), with a price target of $355. The company’s shares closed yesterday at $285.26.

According to TipRanks.com, Bruin is a 4-star analyst with an average return of 4.9% and a 62.1% success rate. Bruin covers the Healthcare sector, focusing on stocks such as Waters Corp, Align Tech, and Agilent.

Illumina has an analyst consensus of Moderate Buy, with a price target consensus of $347.13, which is a 21.7% upside from current levels. In a report released today, Piper Jaffray also maintained a Buy rating on the stock with a $384 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $372.61 and a one-year low of $207.51. Currently, Illumina has an average volume of 1.08M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE).

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts